

# Stuart A Grossman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4179977/publications.pdf>

Version: 2024-02-01

58  
papers

2,380  
citations

293460

24  
h-index

242451

47  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3998  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	0.6	4
2	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
3	Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?. <i>Current Neuropharmacology</i> , 2022, 20, 1383-1399.	1.4	5
4	High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 275-287.	1.1	3
5	CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021, 23, 457-467.	0.6	58
6	A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. <i>Neurosurgery</i> , 2021, 88, 246-251.	0.6	16
7	Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. <i>Advances in Radiation Oncology</i> , 2021, 6, 100545.	0.6	10
8	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
9	Adult precision medicine: learning from the past to enhance the future. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa145.	0.4	11
10	Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2020, 7, 52-58.	1.0	1
11	The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns. <i>Neuro-Oncology</i> , 2020, 22, 1721-1722.	0.6	1
12	Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. <i>Neuro-Oncology</i> , 2020, 22, 1422-1424.	0.6	22
13	Quantifying the utility of a multidisciplinary neuro-oncology tumor board. <i>Journal of Neurosurgery</i> , 2020, 135, 87-92.	0.9	6
14	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 73-79.	3.2	12
15	Brain Metastases as a First Site of Recurrence in Patients Receiving Chemotherapy with Controlled Systemic Cancer: a Critical but Under-Recognized Clinical Scenario. <i>Current Treatment Options in Neurology</i> , 2019, 21, 55.	0.7	7
16	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. <i>Cancers</i> , 2019, 11, 1262.	1.7	99
17	Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy. <i>Neurosurgery</i> , 2019, 85, 441-453.	0.6	33
18	Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression. <i>Cancer Investigation</i> , 2019, 37, 67-72.	0.6	4

#	ARTICLE	IF	CITATIONS
19	ACTR-58. BASELINE REQUIREMENTS FOR NOVEL AGENTS BEING CONSIDERED FOR BRAIN CANCER EFFICACY TRIALS: REPORT OF AN ABTC WORKSHOP. <i>Neuro-Oncology</i> , 2019, 21, vi27-vi27.	0.6	0
20	CMET-02. ESTABLISHING THE SAFETY AND EFFICACY OF A NEW MULTI-AGENT INTRATHECAL TREATMENT PROTOCOL FOR PATIENTS WITH NEOPLASTIC MENINGITIS. <i>Neuro-Oncology</i> , 2019, 21, vi51-vi51.	0.6	1
21	ACTR-37. ASSOCIATION BETWEEN MGMT PROMOTER METHYLATION SCORE AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi21-vi21.	0.6	0
22	DDIS-21. IN VITRO MICRODIALYSIS RECOVERY OF TRAMETINIB. <i>Neuro-Oncology</i> , 2019, 21, vi67-vi67.	0.6	0
23	NIMG-70. A LABEL-FREE APPROACH TO ASSESS CHEMOTHERAPY DRUG CONCENTRATION USING CHEMICAL EXCHANGE SATURATION TRANSFER MRI – A FEASIBILITY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi177-vi177.	0.6	0
24	ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE) Tj ETQq0 0 0 rgBT /Overlo <i>Neuro-Oncology</i> , 2019, 21, vi23-vi23.	0.6	1
25	IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2019, 21, vi122-vi123.	0.6	1
26	The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 347-354.	1.4	25
27	Systemic depletion of lymphocytes following focal radiation to the brain in a murine model. <i>Oncolimmunology</i> , 2018, 7, e1445951.	2.1	15
28	Concurrent BRAF/MEK Inhibitors in <i>BRAF</i> V600â€“Mutant High-Grade Primary Brain Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 343-347.	2.3	46
29	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93
30	Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage. <i>Advances in Radiation Oncology</i> , 2018, 3, 582-590.	0.6	20
31	The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. <i>Fluids and Barriers of the CNS</i> , 2018, 15, 2.	2.4	55
32	Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer. <i>Cancer Investigation</i> , 2018, 36, 356-361.	0.6	9
33	Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor- $\beta$ tyrosine kinase inhibitor, in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now185.	0.6	28
34	The effect of regadenoson on the integrity of the human bloodâ€“brain barrier, a pilot study. <i>Journal of Neuro-Oncology</i> , 2017, 132, 513-519.	1.4	38
35	Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and <i>In Situ</i> Hybridization. <i>Clinical Cancer Research</i> , 2017, 23, 3150-3157.	3.2	52
36	Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2017, 135, 343-351.	1.4	42

#	ARTICLE	IF	CITATIONS
37	Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology. <i>CNS Oncology</i> , 2017, 6, 195-201.	1.2	4
38	Caring for Patients with Newly Diagnosed High-Grade Gliomas. <i>Seminars in Neurology</i> , 2016, 36, 324-329.	0.5	0
39	Acute hemolysis in a patient with a newly diagnosed glioblastoma. <i>CNS Oncology</i> , 2016, 5, 125-129.	1.2	5
40	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 571-579.	0.4	172
41	The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. <i>Journal of Neuro-Oncology</i> , 2016, 126, 433-439.	1.4	41
42	The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. <i>Journal of Neuro-Oncology</i> , 2016, 127, 165-171.	1.4	14
43	Comment on "Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma". <i>British Journal of Cancer</i> , 2015, 113, 1632-1633.	2.9	4
44	How Critical Is the Blood-Brain Barrier to the Development of Neurotherapeutics?. <i>JAMA Neurology</i> , 2015, 72, 381.	4.5	4
45	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1386-1392.	0.6	50
46	A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. <i>Journal of Neuro-Oncology</i> , 2015, 124, 299-305.	1.4	62
47	Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 124, 307-316.	1.4	36
48	High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. <i>Neurology</i> , 2014, 83, 235-239.	1.5	120
49	Blood-based biomarkers for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 113, 345-352.	1.4	35
50	Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States. <i>Clinical Cancer Research</i> , 2010, 16, 2443-2449.	3.2	392
51	A subcutaneous polymeric opioid delivery system for the treatment of cancer pain. <i>European Journal of Pain Supplements</i> , 2010, 4, 257-259.	0.0	0
52	Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4155-4161.	0.8	149
53	Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. <i>Journal of Neuro-Oncology</i> , 2009, 91, 51-58.	1.4	112
54	Current management of glioblastoma multiforme. <i>Seminars in Oncology</i> , 2004, 31, 635-644.	0.8	206

#	ARTICLE	IF	CITATIONS
55	Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas. <i>Seminars in Oncology</i> , 2003, 30, 19-22.	0.8	16
56	Feasibility of Quantitative Pain Assessment in Outpatient Oncology Practice. <i>Journal of Clinical Oncology</i> , 2001, 19, 501-508.	0.8	62
57	Central Nervous System Cancers in First-Degree Relatives and Spouses. <i>Cancer Investigation</i> , 1999, 17, 299-308.	0.6	46
58	Simultaneous leptomeningeal and intramedullary spinal metastases in small cell lung carcinoma. <i>Medical and Pediatric Oncology</i> , 1986, 14, 54-56.	1.0	31